Black Diamond Therapeutics
BDTX
74 hedge funds and large institutions have $209M invested in Black Diamond Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.
682% more call options, than puts
Call options by funds: $3.11M | Put options by funds: $398K
415% more capital invested
Capital invested by funds: $40.6M → $209M (+$169M)
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
48% more funds holding
Funds holding: 50 → 74 (+24)
21.4% more ownership
Funds ownership: 58.92% → 80.31% (+21%)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$5.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.08M |
| 3 |
DM
Deerfield Management
New York
|
+$3.68M |
| 4 |
RI
RTW Investments
New York
|
+$3.47M |
| 5 |
JP Morgan Chase
New York
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.25M |
| 2 |
Millennium Management
New York
|
-$866K |
| 3 |
Two Sigma Advisers
New York
|
-$333K |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$274K |
| 5 |
NM
Newtyn Management
New York
|
-$218K |
BDTX Hedge Fund Activity: Q2 2023 in Review
74 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2023, worth a combined $209M — up 415% from $40.6M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BDTX positions and 8 closed out — a net gain of 24 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was Bellevue Group, adding an estimated $5.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.25M sold.
- 74 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2023, up from 50 in Q1 2023.
- Funds reported $209M of Black Diamond Therapeutics stock for Q2 2023, up 415% quarter-over-quarter.
- 32 funds opened new Black Diamond Therapeutics positions in Q2 2023 and 8 closed out, a net change of +24 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2023 was Bellevue Group, an estimated $5.6M added.
- The largest Black Diamond Therapeutics seller in Q2 2023 was EcoR1 Capital, an estimated $2.25M sold.
Based on aggregated 13F filings for Q2 2023.